Frontage Holdings Corporation (HKG:1521)
Hong Kong · Delayed Price · Currency is HKD 0.7200
-0.0500 (-6.49%)
May 28, 2026, 3:59 PM HKT
Frontage Holdings Market Cap
Frontage Holdings has a market cap or net worth of 1.46 billion as of May 28, 2026. Its market cap has decreased by -35.58% in one year.
Market Cap
1.46B
Enterprise Value
2.16B
Revenue
2.00B
Ranking
n/a
PE Ratio
28.04
Stock Price
0.72
Market Cap Chart
Since May 30, 2019, Frontage Holdings's market cap has decreased from 6.73B to 1.46B, a decrease of -78.29%. That is a compound annual growth rate of -19.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 27, 2026 | 1.56B | -23.00% |
| Dec 31, 2025 | 2.03B | -43.71% |
| Dec 31, 2024 | 3.60B | -23.57% |
| Dec 29, 2023 | 4.71B | -20.20% |
| Dec 30, 2022 | 5.91B | -27.11% |
| Dec 31, 2021 | 8.10B | -6.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 30, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Viva Biotech Holdings | 2.92B |
| HighTide Therapeutics | 1.95B |
| SinoMab BioScience | 1.87B |
| Mabpharm | 1.81B |
| Beijing Biostar Pharmaceuticals | 1.59B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.57B |
| Cutia Therapeutics | 1.51B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.47B |